Pharmather Holdings Ltd (PHRRF)

Pharmather Holdings Ltd. is a Toronto-based specialty pharmaceutical company incorporated in 2019 and listed on OTC Markets as common stock. The company focuses on developing and commercializing pharmaceutical products that use novel delivery approaches intended to support patient outcomes. Its pipeline includes KETARX, a ketamine hydrochloride injection being developed for uses such as Parkinson’s disease, amyotrophic lateral sclerosis, complex regional pain, anesthesia, procedural sedation, depression, surgery, and pain management. Pharmather is also advancing a KETARX microneedle patch for mental health, neurological, and pain disorders, along with a wearable pump version for maintaining general anesthesia in diagnostic and surgical settings. In addition, the company is developing PHARMAPATCH, a microneedle-based platform designed for applications in psychedelics and infectious diseases. Pharmather has licensing and collaboration agreements with BioRAE, the University of Kansas, the University of Arizona, and Queen’s University Belfast to support development of these technologies.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.